# A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Source: https://onco.cc/trials/nct01594723/  
OnCo record `nct01594723` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of 120 mg LY2784544 in myeloproliferative neoplasms, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms is a phase 2 interventional study registered as NCT01594723 by Eli Lilly and Company, with 110 participants enrolled, started 2012-05-22 and due to reach its primary completion in 2015-03-20. Interventions recorded: 120 mg LY2784544.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01594723
- Phase: 2
- Setting: A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms
- Sponsor: Eli Lilly and Company
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT01594723: https://clinicaltrials.gov/study/NCT01594723

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct01594723.json